All In Biotech

Drug Trial Radar · NCT07619898

PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure

PHOENIX- A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis or Hepatitis With Inadequate Response to Corticosteroids in Participants With Unresectable or Metastatic Melanoma Treated With Immune Checkpoint Inhibitors (ICI)

Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Therakos LLCIndustry
Sponsor type
Industry
First posted
Jun 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Extracorporeal photopheresis (ECP) is an immunomodulatory therapy in which the photoactivating agent methoxsalen (also known as UVADEX) is used in combination with ultraviolet A (UVA) light. Immune checkpoint inhibitor therapy is widely used for the treatment of several cancers, including melanoma. However, a common immune-related adverse event associated with this therapy is Immune-related colitis or hepatitis. Corticosteroids are typically the first-line treatment for this condition, but some participants do not respond adequately. The purpose of this study is to evaluate the efficacy of ECP in the treatment of immune-related (ir)-colitis and ir-hepatitis with inadequate response to corticosteroids, and to compare its efficacy to other second-line immunosuppressant therapies. The ECP procedure in this study is performed using the CELLEX® device, a fully closed-loop extracorporeal blood circulation device. The CELLEX device is used in conjunction with methoxsalen.

Conditions

  • Colitis
  • Hepatitis
  • Melanoma (Skin Cancer)

Interventions

  • methoxsalenDrug

    Sterile solution used in conjunction with CELLEX ECP

  • Extracorporeal photopheresis (ECP)Device

    Methoxsalen is used in conjunction with the CELLEX ECP

  • VedolizumabDrug

    Vedolizumab will be administered intravenously

  • InfliximabDrug

    Infliximab will be administered intravenously

  • Mycophenolate Mofetil (MMF)Drug

    Mycophenolate Mofetil will be administered orally or intravenously

  • AzathioprineDrug

    Azathioprine will be administered orally or intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Who are in Steroid-free response at Week 12 for the Randomized Immune-related Adverse Event (irAE) (ir-colitis or ir-hepatitis)Time frame: Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.